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Available online 8 March 2012The use of bone marrowmononuclear cells (BMMCs) has been shown as a putative efficient
therapy for stroke. However, the mechanisms of therapeutic action are not yet completely
known. Mannose receptor (MR) is a subgroup of the C-type lectin receptor superfamily in-
volved in innate immune response in several tissues. Although known primarily for its im-
mune function, MR also has important roles in cell migration, cell debris clearance and
tissue remodeling during inflammation and wound healing. Here we analyzed MR expres-
sion in brains of rats one week after induction of unilateral focal cortical ischemia by ther-
mocoagulation in blood vessels of sensorimotor cortex. Additionally, we evaluated possible
changes in such expression in cortices of rats subjected to ischemia plus treatment with
BMMCs. Our results showed high expression of MR in an unknown GFAP+ cell type and in
phagocytic macrophages/microglia within the lesion boundary zone whereas in the non-
injured (contralateral) cortical parenchyma, low levels of MR expression were observed.
Moreover, therapy with BMMCs induced overexpression of MR in ipsilateral (injured) cortex.
Previous studies from our group have shown functional recovery and decreased neurode-
generation in BMMC-treated rats in the same model of focal cortical ischemia. Thus, we
suggest that ischemic injury induces large increase in MR expression as part of a mecha-
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174 B R A I N R E S E A R C H 1 4 5 2 ( 2 0 1 2 ) 1 7 3 – 1 8 4induction of MR overexpression by BMMCs might increase the efficiency of clearance, being
one of the protective mechanisms of these cells.
© 2012 Elsevier B.V.Open access under the Elsevier OA license.Fig. 1 – Lesion regions. Illustration showing ischemic lesion
extension observed in our experiment, with two regions
identifiable after seven post-ischemic days. White line
indicates the limit between core and boundary zones, and
black line indicates the cortical limit of the lesion (represented
in gray). The core zone is characterized by greatly altered
cytoarchitecture, often with large spaces formed by tissue
cleaning (not shown). The boundary zone presents more
preserved cell organization, favoring a better cytological
analysis. The lateral–medial axis is indicated for the left
hemisphere. STR = striatum; V = lateral ventricle; CC = corpus
callosus.1. Introduction
Systemic administration of bone marrow-derived cells is a
promising strategy to treat stroke. Beneficial effects of these
cells have been described in animal models of ischemic stroke
(Brenneman et al., 2010; Chopp and Li, 2002; de Vasconcelos
dos Santos et al., 2010; Giraldi-Guimarães et al., 2009; Iihoshi
et al., 2004; Kamiya et al., 2008; Mezey, 2007). Moreover, the
feasibility and safety of therapy for stroke in humans with au-
tologous bone marrow cells have already been demonstrated
in clinical studies (Bang et al., 2005; Barbosa da Fonseca et
al., 2010; Battistella et al., 2011; Savitz et al., 2011).
Transplantation of bone marrow mononuclear cells
(BMMCs) has been shown to be an effective protocol for cell
therapy, since BMMCs can be obtained without cultivation
and can be harvested in 1.5–6 h for autologous administration
(Battistella et al., 2011; Brenneman et al., 2010; Iihoshi et al.,
2004; Savitz et al., 2011). Thus, treatment can be performed
during acute phase of stroke (Mendez-Otero et al., 2007).
BMMCs are a heterogeneous cell fraction composed by hema-
topoietic stem, progenitor and differentiated cells, mesenchy-
mal stem cells and endothelial progenitor cells (Orkin, 2000;
Pittenger et al., 1999; Wang et al., 2008; Weissman et al.,
2001). This cell composition gives to BMMCs important thera-
peutic features, such as multipotentiality, chemoattractive-
ness to lesioned tissues and capacity to produce and release
many cytokines and trophic factors (Chopp and Li, 2002;
Crain et al., 2005; Kawamoto and Losordo, 2008; Krause et al.,
2001; Shyu et al., 2006). In fact, BMMC mechanisms of protec-
tion in brain ischemia have been shown to involve mainly
chemoattraction to lesion and local paracrine action, by re-
lease of many anti-inflammatory, angiogenic and neuropro-
tective factors (Mendez-Otero et al., 2007). However, the
whole mechanism is currently being discovered and all re-
storative processes triggered by BMMC paracrine action are
still not completely known.
Here we investigated a possible effect of BMMC treatment
in tissue clearance in cerebral ischemia. For this reason, we
analyzed the expression of mannose receptor (MR), an impor-
tant player in this process. Mannose receptor (MR) is a sub-
group of the C-type lectin receptor superfamily involved in
innate immune response in several tissues, including nervous
tissue (Linehan et al., 1999). MR is a constitutive receptor,
which under influence of immune mediators acts as a pivotal
molecule in the host defense mechanism, being a link
between innate and adaptive immunity (Areschoug and
Gordon, 2008). Although MR is known primarily for its innate
immune function, it also has an important role in cell migra-
tion, intracellular signaling, cell debris clearance and tissue
remodeling during inflammation and wound healing (Gazi
and Martinez-Pomares, 2009; Taylor et al., 2005).
Thus, we analyzed MR expression in the cerebral cortex of
rats that underwent focal ischemia induced by thermocoagu-
lation of blood vessels in primary motor and somatosensorycortices. Additionally, we evaluated possible changes in corti-
cal pattern of MR expression in rats subjected to cortical is-
chemia followed by treatment with BMMCs. We chose the
time window of a week after ischemia induction for our ana-
lyses. This post-ischemia time is likely close to the end of
the acute phase, since the cortical tissue is almost degener-
ated, but not completely (Szele et al., 1995), and inflammatory
events and clearance are still occurring. Moreover, recent re-
ports have suggested that systemically injected BMMCs mi-
grate to an injured cortex as fast as 1 h after injection, but
they undergo progressive death, being almost absent in an is-
chemic lesion 7 days after injection (Brenneman et al., 2010).
We repeated the previously used protocol of treatment 24 h
after ischemia induction (Giraldi-Guimarães et al., 2009). Our
rationale was to perform analysis in a time point still inside
the acute phase, but with as few as possible exogenous
BMMCs. Since the mononuclear fraction contains monocytes
with potential to differentiate in MR-expressingmacrophages,
their presence in earlier time points could mask the intensity
of MR expression by endogenous cells within the ischemic
lesion.2. Results
In accordance with previous descriptions (de Vasconcelos dos
Santos et al., 2010; Giraldi-Guimarães et al., 2009), our proce-
dure of thermocoagulation induced a consistent ischemic
lesion that included the six cortical layers, sparing white
matter (Fig. 1). The time window after ischemia induction
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greatly advanced, as previously described by Szele et al.
(1995). Differences in the level of cytoarchitecture impairment
led us to recognize two main lesion zones: a core zone, with
great level of tissue degeneration, and a boundary zone, with
less tissue disorganization, which favored histological analy-
sis (Fig. 1). Although Man-BSA+ (Fig. 2B) and MR+ (not shown)
cells have been observed in the lesion core zone, the high
level of cell degeneration and cytoarchitecture impairment
hindered double-labeling visualization in this region. We fo-
cused our double-labeling analyses in the less degenerated le-
sion boundary zone. We performed these analyses in BMMCs
and control (ischemic-untreated) animals. No qualitative dif-
ference in pattern of labeling was observed between groups.
2.1. A C-type lectin receptor (MR) is active in the ischemic
lesion
Labeling with Man-BSA revealed a large number of positive
cells within the ischemic lesion (Figs. 2A and B). Stained cells
always presented spherical (amoeboid) morphology, and
were not observed in unimpaired cortical parenchyma. Out
of the lesion, Man-BSA+ cells were only observed inmeningeal
space and had no relation to lesion, since they were observed
along the whole cerebral cortex, in both hemispheres (Fig. 2C).Fig. 2 – Pattern of staining with Man-BSA in the ischemic cortical
representative coronal section reacted with Man-BSA showing th
(left) cortical hemisphere of a control animal, at the anterior level o
within the lesion. Arrows point the limit of the ischemic lesion. (B
the same animal, at more posterior level of the lesion. This imag
illustrating the difference between stained cells of boundary and
usually have higher cell bodies and are more easily identifiable
section of a BMMC-treated animal, showing the surface of the con
meningeal space, frequently observed in whole cortical surface.Labeling with an anti-MR antibody (against a C-terminal
peptide) revealed a similar pattern of expression, although
with a much lower number of stained cells in the lesion core
zone and in the meningeal space (not shown).
2.2. MR is expressed by GFAP+ cells and phagocytic
macrophages/microglia in the lesion boundary zone
To characterize MR-expressing cell types within the ischemic
lesion, double-labeling analyses were performed. Lack of
Man-BSA and MR labeling in unaffected cortical parenchyma
and the constant spherical morphology of labeled cells led
us to disconsider neurons as a possible identity. By previous
reports, oligodendrocytes do not express MR (Burudi and
Régnier-Vigouroux, 2001), and this cell type was also disre-
garded. We evaluated if these cells are reactive astrocytes by
double-labeling with anti-GFAP. As expected in rodents (but
not humans, see Liu et al., 2004), GFAP+ cells located in unim-
paired cortical parenchyma, morphologically identified as
non-reactive astrocytes, were negative to Man-BSA and anti-
MR (Figs. 3C1–4). GFAP+ cells adjacent to the lesion limit,
whose morphology is suggestive of reactive (gemistocytic)
astrocytes, were also negative to Man-BSA and anti-MR
(Figs. 3A1–4 and D1–4). GFAP+ cells were observed in the lesion
boundary zone, but this labeling was weaker and theirlesion induced by thermocoagulation. (A) Photomontage of a
e whole lateral–medial extension of the lesion in the injured
f the lesion. Labeled cells (bright green points) were observed
) Photomicrograph taken from other representative section of
e shows the lateral part of the lesion in higher magnification,
core zones of the lesion. In boundary zone, stained cells
(arrows). (C) Photomicrograph taken from a representative
tralateral (right) cortex. This image illustrates stained cells in
Scale bars=100 μm.
Fig. 3 – Double-labeling anti-GFAP+Man-BSA and antiGFAP+anti-RM in the lesion boundary zone. (A1–4) Photomicrographs of
a same field taken from a representative section of a control animal after double-labeling with anti-GFAP and Man-BSA. These
images show the lateral part of the lesion limit (pointed by arrows in A4), which can be identified by different cytoarchitecture
and nucleus size within and outside the lesion (see A3). Note that Man-BSA+ cells are located within the lesion boundary zone
(A2, boundary in A4). In this region, many of these cells are also GFAP+. GFAP+ cells placed outside the lesion (presumably
forming the glial scar) are negative to Man-BSA. Scale bar in A4=50 μm. (B1–4) Photomicrographs of a same field illustrating, in
higher magnification, the lesion boundary zone shown in A1–4. Many GFAP+/Man-BSA+ cells can be observed (arrows point
some of them), although GFAP+ cells negative to Man-BSA are also found (B4). Some Man-BSA+ cells negative to GFAP were
observed (not shown). Scale bar in B4=20 μm. (C1–4) Photomicrographs of a same field taken from a representative section of
another control animal after double-labeling with anti-GFAP and Man-BSA. These images illustrate that GFAP+ cells and
processes are negative to Man-BSA in unimpaired cortical parenchyma. Scale bar in C4=20 μm. (D1–4) Photomicrographs of a
same field taken from a representative section of a control animal after double-labeling with anti-GFAP and anti-MR. The
pattern of MR labeling is similar to that seen with Man-BSA labeling. Double-labeled cells are observed in the lesion boundary
zone, and GFAP+ cells placed outside the lesion are negative to MR. Scale bar in D4=50 μm.
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tive astrocyte (Figs. 3A1, B1 and D1). Many of these cells were
double-labeled with Man-BSA and anti-MR (Figs. 3A1–4, B1–4
and D1–4). These results indicated that part of MR expressing
cell populating within the boundary zone is composed of a
GFAP+ cell type, but which is probably not a type of astrocyte.
Man-BSA+ and MR+ cells negative to GFAP were also ob-
served, indicating at least a second identity for these cells.
Since the morphology of MR expressing cells within theboundary zone is similar to phagocytic macrophage/microglia,
we evaluated this possible identity for these cells by double-
labelingwith IB4. IB4+/Man-BSA+ cells were observed only with-
in the boundary zone (Figs. 4A1–4). These double-labeled cells
presented amoeboidmorphology, indicative of phagocyticmac-
rophage/microglia (Figs. 4B1–4). The same patternwas observed
in IB4+ant-MR double-labeling (Figs. 4C1–4 and D1–4).
To confirm morphological criteria, phagocytic macro-
phages/microglia were identified using an antibody directed
Fig. 4 – Double-labeling IB4+Man-BSA and IB4+anti-RM in the lesion boundary zone. (A1–4) Photomicrographs of a same field
taken from a representative section of a control animal after double-labeling with IB4 and Man-BSA. These images show the
medial part of the lesion limit (pointed by arrows in A4). IB4+ (A1), Man-BSA+ (A2) and double-labeled (A4) cells are located
within the lesion boundary zone (boundary in A4). Scale bar in A4=50 μm. (B1–4) Photomicrographs of a same field illustrating,
in highermagnification, the lesion boundary zone shown in A1–4. Themorphology of IB4+ is typical of phagocyticmacrophage/
microglia (see Fig. 3). Some IB4+/Man-BSA+ cells are pointed by arrows. Scale bar in B4=20 μm. (C1–4) Photomicrographs of a
same field taken from a representative section of a BMMC-treated animal after double-labeling with IB4 and anti-MR. As
observed in the Man-BSA labeling, IB4+/MR+ cells are observed in the lesion boundary zone. Scale bar in C4=50 μm. (D1–4)
Photomicrographs of a same field illustrating, in higher magnification, the lesion boundary zone shown in C1–4. Arrow points
an example of double-labeled cell. Scale bar in D4=20 μm.
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which expression is highly increased when these cells became
phagocytic. Double-labeling with IB4 and anti-ED1 revealed
IB4+ cells negative to ED1 in unaffected parenchyma
(Figs. 5A1–3). These cells had typical morphology of resting
microglial cells (Fig. 5A1). IB4+ cells with typical morphology
of activated microglial cells were observed close to the lesion
(Fig. 5B1), and these cells presented slight but detectable ED1
expression (Figs. 5B1–3), suggesting a starting phagocytic ca-
pability. Confirming morphological analysis, most of IB4+
cells of boundary zone were double-labeled with anti-ED1(Figs. 5C1–3), indicating they are phagocytic macrophage/
microglia. Double-labelingwith anti-ED1 andMan-BSA revealed
double-labeled cells within the boundary zone, confirming
morphological conclusion that part of MR expressing cells in
this region are phagocytic macrophage/microglia (not shown).
2.3. Ischemic lesion and treatment with BMMCs induced
increased expression of MR in injured cortex
Double-labeling analyses were useful for qualitative analysis
and showed clear evidence of increased MR expression within
Fig. 5 – Double-labeling IB4+anti-ED1 to identify phagocytic stage. (A1–3, B1–3 and C1–3) Photomicrographs taken from a
representative section of control animal after double-labeling with IB4 and anti-ED1. (A1–3) Images from ipsilateral unimpaired
cortical parenchyma showing IB4+ cells with typical morphology of inactivated (resting) microglia (some pointed by arrows).
These cells were negative to ED1. (B1–3) Images from a region close to the lesion limit (out of the image upper border). IB4+ cells
were slightly positive to ED1 (some pointed by arrows), and presented typical morphology of activated (reactive) microglia.
(C1–3) Images from lesion boundary zone showing the large number of IB4+ cells positive to ED1 (some pointed by arrows).
These cells presented typical morphology of phagocytic (amoeboid) microglia. Scale bars=20 μm.
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the complex pattern of staining hampered an accurate selec-
tion of image fields and standardization of sample for quanti-
fication by cell counting or densitometric analysis. For this
reason, to verify the effect of BMMC treatment in the level of
MR protein expression, we performed quantitative analysis
by densitometric measurement of protein bands obtained in
immunoblotting procedure (Fig. 6).
Statistical analysis revealed no significant interaction be-
tween factors (side×treatment; F=6.29; p=0.07), and signifi-
cant effects of side (F=45.75; p<0.01) and treatment (F=19.42;
p<0.05). Comparisons among sides showed significantly
more MR protein in ipsilateral than in contralateral cortex, in
both groups (Figs. 6B and C). No significant difference was ob-
served between BMMCs and control contralateral cortices
(p=0.23) (Fig. 6C), and this low expression was not different
from ipsilateral and contralateral cortices of non-operated
animals (Fig. 6B). Furthermore, comparison between ipsilat-
eral cortices revealed a significantly greater quantity of MR
protein in BMMC group (Figs. 6B and C). These results show
that a sizeable MR expression was induced within the lesion,
and that in BMMC-treated animals this expression was
increased.3. Discussion
We observed a largely increased MR expression within the
ischemic cortical lesion a week after ischemia induction.
Unimpaired cortical parenchyma presented no detectable ex-
pression in histological analysis and low expression in immu-
noblotting assay. These results suggest that ischemia induces
a high expression of this receptor in damaged tissue. We la-
beled MR by two ways, which showed similar pattern of stain-
ing, particularly in the lesion boundary zone, although with
differences in the number of stained cells in the lesion core
zone and in meningeal space. Antibody anti-MR revealed MR
protein, and mannosylated neoglycoprotein revealed the
presence of a mannose receptor, i.e., its ability to bind to a
specific ligand. Thus, in addition to a conclusion that MR ex-
pression is largely induced by ischemia, we can also infer
that MR (and/or a member of its family) is found in a chemi-
cally active form. Mannosylated residues are also recognized
by other members of the C-type lectin receptor superfamily
(Linehan et al., 1999). However, the expression of these other
members is not expected in our experiments, since expres-
sion of Endo180 is predominantly restricted to cells of
Fig. 6 – Quantitative analysis of MR expression by immunoblotting procedure. (A) Illustration showing the regions dissected for
immunoblotting analysis. Ipsilateral region (I) was obtained by dissection of cortical gray matter located between the lesion
and the cerebral longitudinal fissure, including the medial boundary zone of the lesion. The contralateral cortical gray matter
homologous to injured cortex constituted the contralateral region (C). In non-operated animals (normal), this pattern of
dissection was maintained (considering the presumable location of the lesion in left hemisphere). (B) Immunoreactive bands
from the two films obtained in immunoblotting procedure for detection of the MR protein. Although not quite compact, bands
were located around the correct position for the MR protein molecular weight (180 kDa). No other band was detected along the
lines. Note increased MR protein expression in ipsilateral region (ipsi) in BMMCs and control groups. Contralateral region of
BMMCs and control groups showed lower MR expression, similar to that observed in normal animals. The numbers in
parentheses mean an arbitrary identification for each animal in each group used in this experiment. (C) Bar graph summarizing
the densitometric analysis of the bands. Statistical analysis revealed significant higher MR expression in ipsilateral than in
contralateral region in both groups. Furthermore, the comparison between ipsilateral regions revealed higher MR expression in
BMMCs than in control group. In (A): STR = striatum; V = lateral ventricle; CC = corpus callosus. In (C): BMMC group, n=3; control
group, n=3; each vertical bar+error bar=mean+S.E.M; *=p<0.05, t test).
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(Engelholm et al., 2009) and Dec 205, tested in parallel with
MR, was not reported in the brain (Linehan et al., 1999). Fur-
thermore, we used an isolation method that eliminates
unwanted cell types present in marrow aspirate, of which a
small percentage (estimated at about 0.001 to 0.01%) grow as
fibroblastic cells (mesenchymal stem cells; Pittenger et al.,
1999).
Previous reports demonstrated that MR expression in mu-
rine brain is higher in the first week of life and dramatically
decreases thereafter, beingmaintained at a low level through-
out adulthood. During development and postnatal age, sites
of most intense expression aremeninges, followed by cerebral
cortex, brain stem and cerebellum. With age, this expression
tends to be maintained in a region such as the cerebral cortex
and brain stem, although it disappears from others such as
the hippocampus (Burudi and Régnier-Vigouroux, 2001).
Furthermore, MR is mainly expressed by meningeal andparenchymal perivascular macrophages (Galea et al., 2005),
besides also by neurons and astrocytes (Burudi and Régnier-
Vigouroux, 2001). Galea et al. (2005) demonstrated that after
induction of different types of inflammatory lesions in cere-
bral parenchyma, MR expression still remains restricted to
perivascular macrophages, and activated microglia and in-
vading hematogenous leukocytes are MR negative. They
argued that perivascular macrophages might remain in vas-
cular niche, or theymight looseMR expression aftermigration
to the inflamed region. We showed discrepant results, since
we observed a large MR expression within the ischemic corti-
cal lesion, which is known to induce intensive inflammatory
tissue response (Huang et al., 2006). And part of MR positive
cell population within the ischemic lesion was undeniably
phagocytic macrophages/microglia. We are not able to explain
these different results, but it might represent differences in
physiopathological characteristics among our model of ische-
mia and the different protocols of lesion used in the previous
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lesion induction survival times spent until animal sacrifice
used in each work.
Microglia, astrocytes, immature neurons, olfactory
ensheathing cells and Schwann cells express MR (Baetas-da-
Cruz et al., 2009a; Liu et al., 2004; Macedo-Ramos et al., 2011;
Régnier-Vigouroux, 2003) but there is no evidence that either
mature oligodendrocytes or their precursors express it
(Burudi and Régnier-Vigouroux, 2001; Galea et al., 2005).
These data led us to look for microglial and astrocytic identi-
ties for MR expressing cells found within the lesion boundary
zone. As said above, our double-labeling confirmed that part
of the MR expressing cells were phagocytic macrophages/
microglia. We also found a MR expressing GFAP+ cell popula-
tion specific of the lesion boundary zone, but their morpholo-
gy was not indicative of reactive or other known type of
astrocyte. We are not able to classify this GFAP+ cell popula-
tion, but in the light of recent reports, these cells might corre-
spond to perilesional NG2 cells-derived GFAP+ cells, described
after neocortical stab wound injury (Komitova et al., 2011).
Moreover, they might also correspond to pericytes scar form-
ing migrated from parenchymal perivascular niche (Göritz et
al., 2011) and/or ischemia-induced neural stem/progenitor
cells migrated from meningeal perivascular niche (Nakagomi
et al., 2011). But in these two last hypotheses, we might
suppose transdifferentiation in a GFAP expressing cell type,
since they were not found to be GFAP+ (Göritz et al., 2011;
Nakagomi et al., 2011). Further investigations are necessary
to clarify the real identity of these cells. We cannot exclude
the possibility that part of MR expressing cells are formed by
administered BMMCs. However, the number of these hypo-
thetical MR-expressing BMMCs is likely to be very low, since
it has been shown that BMMCs are found within the ischemic
lesion 1 h after injection, and then undergo progressive death
until they are almost absent after 7 days (Brenneman et al.,
2010).
We have previously demonstrated in the same model of
ischemia that treatment with BMMCs promoted significant
sensorimotor functional recovery and decreased neurodegen-
eration in the periphery of the ischemic lesion (Giraldi-
Guimarães et al., 2009). Here we observed that BMMCs seem
to promote overexpression of MR in ipsilateral (impaired)
cortex. Together, previous and current data might suggest
functional relation between functional recovery, decreased
neurodegeneration and increased MR expression. MR involve-
ment in clearance has been already demonstrated, since there
are evidences showing that MR might interact with other pat-
tern recognition receptors (PRRs) to mediate signal transduc-
tion pathways (Gazi and Martinez-Pomares, 2009). PRRs can
recognize dying cells through damage-associated molecular
patterns (DAMPs), and this recognition depends on changes
in membrane phospholipids or glycoproteins via alterations
in glycation patterns (Bianchi, 2007; Miller et al., 2011).
DAMPs are also considered important in embryogenesis,
when apoptosis is prominent (Bianchi, 2007). Molecules and
cellular components potentially found in areas of trauma
that can bind to MR include lysosomal enzymes, tissue plas-
minogen activator, red blood cells, factor X, complement pro-
tein iC3b and fibrinogen (Ishihara et al., 1998; Issekutz et al.,
1999; Taylor, 1993). Furthermore, a recent study providesevidence that the calcium-binding protein oncomodulin,
combined with elevated cAMP and presence of D-mannose,
is important to promote retinal ganglion cell regeneration fol-
lowing optic nerve injury (Benowitz and Yin, 2010). Involve-
ment of mannose ligands was not investigated, but the need
for D-mannose presence might suggest activation of MR and
its possible promoting effect in axonal regeneration. These
data highlight an interesting paradox concerningmannose re-
ceptors, because it is also known that mannosylated ligands
are capable of inducing a macrophage state that leads to axo-
nal injury through the cavitation mediated by astrocytes
(Fitch et al., 1999).
Thus, our results suggest that induction of overexpression
of MR within the ischemic lesion by BMMC treatment might
contribute to the restorative effect of these cells, since MR is
part of a mechanism for clearance of DAMPs, such as soluble
immune components, cell debris, cytotoxic substances, mye-
lin glycoproteins and degrading enzymes. More effective
clearance might turn damaged tissue more permissive to
plastic changes and regeneration of affected neuronal projec-
tions. Furthermore, it might also remove more efficiently
toxic molecules, contributing to decreased neurodegeneration
in periphery of the cortical lesion after BMMC treatment ob-
served in our previous work (Giraldi-Guimarães et al., 2009).
The mechanism of action of bone marrow-derived cells
has been described to involve migration to the site of injury
and engrafting. Furthermore, three mechanisms might also
be involved: cell fusion, differentiation (or “transdifferentia-
tion”) into neural cell types and releasing of many trophic fac-
tors, cytokines and extracellular matrix components into the
ischemic lesion (Chopp and Li, 2002; Maltman et al., 2011).
The role as a “factory” of trophic factors and extracellular
matrix molecules has been shown to be the most promising
action, promoting angiogenesis, neuroprotection (reduction
of apoptosis), modulation of inflammatory response, reduc-
tion of glial scar and facilitation of axonal regeneration and
plastic rewiring of neuronal connections (Chopp and Li, 2002;
Crain et al., 2005; Krause et al., 2001; Li et al., 2005; Maltman
et al., 2011; Shyu et al., 2006). Our results seem to include a
new putative mechanism, since the increasing of clearance
might also be taking place. However, more studies should be
performed to elucidate this question.
Taken together, our data suggest a possible involvement of
MR in a regenerativemechanism, through efficient removal of
cellular debris and inflammatory components, triggered by
damage process in acute phase of brain injury.4. Experimental procedures
4.1. Animals and chemicals
Albino Wistar rats with ages ranging from 2 to 5 months were
used in the present study. All animals were housed in a
colony room with controlled temperature, and with food and
water available ad libitum. Our experiments were carried out
in accordance with National Institute of Health Guide for the
Care and Use of Laboratory Animals (NIH Publications No.
80-23), and were approved by the Committees for Use of
Experimental Animals of our institutions.
181B R A I N R E S E A R C H 1 4 5 2 ( 2 0 1 2 ) 1 7 3 – 1 8 4Enhanced chemiluminescence (ECL) kit and secondary
antibodies conjugated to horseradish peroxidase (HRP) were
obtained fromAmershamPharmaciaBiotech (São Paulo, Brazil).
Most of reagents and chemicals were purchased from Sigma-
Aldrich Co. (St. Louis, MO, USA). Exceptions are indicated in
the text.
4.2. Surgical procedures
Ischemic lesion was induced by thermocoagulation of blood
into pial blood vessels of primary motor and somatosensory
cortices, as previously described (de Vasconcelos dos Santos
et al., 2010; Giraldi-Guimarães et al., 2009). Briefly, animals
were anesthetized with ketamine hydrochloride (100 mg/kg,
i.p.) and xylazine hydrochloride (10 mg/kg, i.p.) and placed in
a stereotaxic apparatus. A craniotomy was made to expose
left frontoparietal cortex (+2 to −6 mm from bregma in
antero-posterior axis; according to the atlas of Paxinos and
Watson, 1998). Superficial blood vessels were thermocoagu-
lated transdurally by approximation of a hot probe to dura
matter. Skin was then sutured and animals were kept warm
under a hot lamp and returned to the colony room after recov-
ery from the anesthesia.
4.3. Obtainment and transplantation of BMMCs
Bone marrows were obtained from donor normal albino
Wistar rats. Animals were anesthetized with ketamine hydro-
chloride (100 mg/kg, i.p.) and xylazine hydrochloride (10 mg/
kg, i.p.) and then sacrificed. Femoral and tibial bones were dis-
sected and their bone marrows were extracted with serum-
free DMEM-F12 (GIBCO BRL, Grand Island, NY, USA). Bone
marrow cells were mechanically dissociated and separated
by centrifugation for 30 min in Histopaque. BMMCs were
collected, washed and resuspended with phosphate-buffered
saline (PBS).
All ischemic animals were injected into the left jugular
vein approximately one day after ischemia induction. In a
group of animals (BMMC group; n=6) each animal was
injected with 500 μl of PBS containing 3×107 cells, and inTable 1 – Summary of markers used in double-labeling.
Primary marker Dilution Secon
– – Fluorescein isothiocyana
mannosylated bovine ser
Antibody generated against the
C-terminal cytoplasmic portion of
MR (anti-MR); rabbit IgGa
1:100 Alexa Fluor® 488-conjugat
antibodyb
Anti-glial fibrillary acidic protein
(GFAP) antibody; mouse IgG
1:100 Cy3-conjugated goat anti
antibodyb
Biotinylated-isolectin B4 (IB4) 1:200 CY3-conjugated streptavi




a Kindly donated by Dr. Anne Régnier-Vigouroux.
b Molecular Probes, Eugene, OR, USA.
c And other GFAP+ cell types.another group (control group; n=6) each animal was injected
with 500 μl of PBS. This cell dose was chosen since it has
been shown in the literature that systemic treatment with 1–
3×107 cells is effective to promote recovery, including previ-
ous studies from our research group (de Vasconcelos dos
Santos et al., 2010; Giraldi-Guimarães et al., 2009; Iihoshi et
al., 2004; Kamiya et al., 2008; yang et al., 2011).
4.4. Histological procedures and double-labeling
After seven post-ischemic days, three animals from each ex-
perimental group were sacrificed and intracardially perfused
with 0.9% NaCl solution followed by 4% paraformaldehyde,
in 100 mM phosphate buffer (pH 7.4). Brains were removed
and immersed in 100 mM phosphate buffer containing 20%
sucrose for 24 h at 10 °C. Brains were sectioned in the coronal
plane at 30 μm of thickness at −20 °C on a CM 1850 cryostat
(Leica Instruments GmbH, Heidelberg, Baden-Wurttemberg,
Germany). Sections were then washed in PBS and preincu-
bated in PBS+0.3% Triton X-100 with 10% normal goat serum
for 60 min at room temperature. After that, they were incubat-
ed overnight at 10 °C in the same solution to which pairs of
specific markers were added. After washing with PBS, bound
primary makers were revealed by incubation with correspon-
dent secondary markers in PBS for 2 h at room temperature.
All sections were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). Table 1 summarizes used primary and
secondary markers. Pairs of markers used for double-labeling
are described in the Results section.
A histochemical assay with fluorescein isothiocyanate
(FITC)-conjugated mannosylated bovine serum albumin
(Man-BSA) binding was performed in order to verify the pres-
ence of a mannose receptor with the active C-type lectin-like
domains (CTLDs). Some sections were washed in Ringer solu-
tion and incubated with 50 μg/ml Man-BSA diluted in Ringer
solution containing 5 mM CaCl2 plus 1% BSA at 37 °C for 1 h.
Controls were obtained by incubation of the sections with
250mMD-mannose or ~1.1 μMHRPdiluted in the same labeling
solution followed by washing and incubation with 50 μg/ml
Man-BSA, as previously described (Baetas-da-Cruz et al., 2009b).dary marker Dilution To label
te (FITC)-conjugated
um albumin (Man-BSA)
1:100 Active C-type lectin like
domains (CTLDs) of
mannose receptors
ed goat anti-rabbit IgG secondary 1:200 MR
-mouse IgG secondary 1:400 Astrocytes c
din b 1:200 Macrophage/microglia
i-mouse IgG secondary
r with Man-BSA), and Alexa




182 B R A I N R E S E A R C H 1 4 5 2 ( 2 0 1 2 ) 1 7 3 – 1 8 4Regarding MR protein staining, we used two different sera
(kindly donated by Dr. Anne Régnier-Vigouroux). One, gener-
ated against MR C-terminal cytoplasmic portion, has worked
better in immunohistochemistry (IHC) than in western blot
assays in previous tests from our collaborators, and was
used for double-labeling (Table 1). The other, which was
made using the whole molecule and that recognizes an extra-
cellular epitope (called K1K2 antibody), has worked better in
western blot than in IHC. Thus K1K2 antibody was used in im-
munoblotting analysis, as described below.
4.5. Electrophoresis (SDS-PAGE) and immunoblotting
After seven post-ischemic days, three animals of both experi-
mental groups were sacrificed for the quantification of MR
protein by immunoblotting. Normal (non-operated) animals
were also sacrificed and used in this analysis. Animals were
decapitated under deep anesthesia and their brains were re-
moved from the skull. In ischemic animals, the cortical tissue
located between the lesion, the cerebral longitudinal fissure
(ipsilateral region) and the contralateral cortex homologous
to the lesioned cortex (contralateral region) were dissected
separately (Fig. 6A). In normal animals, the same regions
were separately dissected (left cortex located between the pre-
sumptive place of the lesion and the longitudinal fissure and
right cortex homologous to the presumptive place of the le-
sion). Care was taken to dissect only the six cortical layers
(gray matter). Tissues were then homogenized at 4 °C in a
lyses buffer containing 20 mM Tris–HCl (pH 7.0), 150 mM
NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 0.2%
triton-X-100, 10 μg/ml leupeptin, 10 μg/ml soybean trypsin in-
hibitor and 2 μg/ml aprotinin. Thus, each animal generated
two homogenates (ipsilateral and contralateral sides). All ho-
mogenates were centrifuged at 4 °C and the supernatants
were collected to be used in electrophoresis.
Protein concentration of supernatantswas determined by the
Bradford's technique. For each supernatant, a sample containing
30 μg of protein was collected and mixed with electrophoresis
sample buffer containing 50mMTris–HCl (pH 6.8), 2% (w/v) sodi-
um dodecyl sulfate (SDS), 5% (v/v) β-mercaptoethanol and 10%
(v/v) glycerol. All samples were boiled for 4 min prior to loading
in a 12.5% SDS-polyacrylamide gel. Mini-PROTEAN 3 Electro-
phoresis Module (BioRad Laboratories Inc., Hercules, CA, USA)
was used.After separated in gel, proteinswere transferred to ni-
trocellulose membranes (0.45 μm pore), which were blocked in
PBS-tween (0.05% tween-20 in 10mM PBS) containing 5%
skimmed powdered-milk for 1 h. Membranes were incubated
in the same solution added by K1K2 antibody (against MR pro-
tein; rabbit IgG polyclonal; dilution 1:1000). After washes in
PBS-tween, membranes were incubated with HRP-conjugated
secondary antibody (goat anti-rabbit; dilution 1:3000, in PBS-
tween) for 2 h. After washes in PBS-tween, immunoreactive
bands were then visualized by films impregnated using ECL
kit, in accordance to manufacturer's instructions.
4.6. Data analysis
Sections reacted for double-labeling were analyzed under
fluorescent illumination in an Axioplan microscope (Carl
Zeiss Inc., Germany), using fluorescein, rhodamine and DAPIfilters. Color images were captured using a Zeiss AxioCam digi-
tal camera connected to this microscope and to a PC computer
with Zeiss Axiovision 4.8 Software. For illustration, grayscale
conversion, brightness/contrast adjustments and artwork
were made using Adobe Photoshop software (Adobe Systems
Inc., San Jose, CA, USA).
Films obtained in immunoblotting procedure were
scanned to capture their images. Optical density (OD) of each
immunoblot was measured using the NIH ImageJ 1.44b soft-
ware. For each side of each animal, final value was: blot OD
minus film background OD. All images were analyzed without
any modification. For illustration, grayscale conversion and
artwork were made using Adobe Photoshop software (Adobe
Systems Inc., San Jose, CA, USA).
For statistical analysis, repeated measures two-way
ANOVA (“side” versus “treatment”; side as thematched factor)
was used. Paired t test was used for comparisons among sides
inside each group, and unpaired t test for comparisons among
groups inside each side. Level of significance was always set
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